Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Single-tablet HIV regimen (INSTI + 2× NRTI)

Bictegravir with emtricitabine and tenofovir alafenamide

Brand names: Biktarvy

This is a single-tablet, complete antiretroviral regimen combining the integrase strand transfer inhibitor bictegravir with two nucleos(t)ide reverse transcriptase inhibitors, emtricitabine and tenofovir alafenamide, used to treat HIV-1 infection.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Bictegravir blocks integration of viral DNA into the host genome, while emtricitabine and tenofovir alafenamide are incorporated by reverse transcriptase to terminate the growing viral DNA chain.

Prescribing in practice

  • All patients should be tested for hepatitis B before starting, as stopping the emtricitabine and tenofovir components can cause severe hepatitis B flares requiring monitoring after discontinuation.
  • Polyvalent-cation antacids and supplements impair bictegravir absorption and must be separated in time or taken with food as directed in the SPC.
  • It is not recommended in significant renal impairment below the licensed threshold and certain anticonvulsants and rifamycins reduce bictegravir exposure.

Monitoring

Monitor renal function and, where indicated, hepatitis B status, alongside HIV viral load and CD4 response.

Counselling the patient

  • Take one tablet once daily and never run out, as missed doses risk resistance.
  • Separate this from indigestion remedies, calcium, magnesium or iron, or take with food as advised.
  • Do not stop this medicine without specialist advice, especially if you have hepatitis B.

Evidence & guidelines

Efficacy and tolerability were established in the GS-US-380 phase 3 programme supporting its use as first-line therapy.

Reference: BHIVA HIV guidelines; EACS; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways